MDCX — Medicus Pharma Income Statement
0.000.00%
- CA$64.10m
- CA$57.06m
Annual income statement for Medicus Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.131 | 0.088 | 0.142 | 0.978 | 6.28 |
| Operating Profit | -0.131 | -0.088 | -0.142 | -0.978 | -6.28 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.131 | -0.088 | -0.142 | -1.69 | -6.78 |
| Net Income After Taxes | -0.131 | -0.088 | -0.142 | -1.69 | -6.78 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.131 | -0.088 | -0.142 | -1.69 | -6.78 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.131 | -0.088 | -0.142 | -1.69 | -6.78 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.526 | -0.267 | -0.043 | -0.898 | -1.01 |